Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | Immunotherapy for frontline treatment of ALL: inotuzumab ozogamicin and blinatumomab

Nicolas Boissel • 15 Jun 2024
EHA 2024
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Inotuzumab ozogamicin
ECOG-E1910

Nicolas Boissel, MD, PhD, Saint-Louis Hospital, Paris, France, discusses advancements in immunotherapy for frontline treatment of acute lymphoblastic leukemia (ALL). Trials show promising results with inotuzumab ozogamicin combined with low-dose chemotherapy for induction therapy, and blinatumomab as a consolidation treatment for patients responding well to induction. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nicolas Boissel

T-cell engagers and treating relapsed ALL
Bijal Shah et al. • 29 Sep 2022
Novel treatment strategies in ALL
Nicholas Short et al. • 29 Sep 2022
Should patients with certain ALL subtypes be considered for alloSCT irrespective of MRD status? 2:30
Should patients with certain ALL subtypes be considered for alloSCT irrespective of MRD status?
Nicolas Boissel • 15 Jun 2024
The role of asparaginase in the treatment of ALL 3:02
The role of asparaginase in the treatment of ALL
Nicolas Boissel • 15 Jun 2024

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals